If you purchased or acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2025 initial public offering (“IPO” or the “Offering”); and/or (b) securities between October 1, 2025 and December 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate i ...

Core Viewpoint - A class action securities lawsuit has been filed against Beyond Meat, Inc. for alleged securities fraud affecting investors between February 27, 2025, and November 11, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that Beyond Meat's defendants made false statements regarding the book value of certain long-lived assets, which exceeded their fair value, indicating a likely need for a material, non-cash impairment charge [2]. - It is claimed that this situation could impair Beyond Meat's ability to timely file periodic reports with the SEC, rendering the defendants' public statements materially false and misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until March 24, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ultragenyx-pharmaceutical-inc-loss-submission-form-2/?id=183592&fro ...

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation for allegedly failing to disclose acquisition offers from Owens Corning while repurchasing its own stock, potentially misleading investors during the Class Period from June 5, 2023, to February 8, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who sold Masonite common stock during the specified Class Period [2]. - Investors have until April 7, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The allegations state that Masonite was aware of multiple formal acquisition offers from Owens Corning to purchase all outstanding shares at prices significantly above the market prices during the Class Period [3]. - The lawsuit claims that Masonite had an obligation to disclose these acquisition offers or refrain from repurchasing its stock from investors [3]. Group 3: Next Steps for Investors - Investors who purchased or acquired Masonite shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - There is no cost or obligation for investors to inquire about their rights or the lawsuit [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BellRing Brands, Inc. (NYSE: BRBR). Shareholders who purchased shares of BRBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bellring-brands-inc-loss-submission-form/?id=183287&from=4 CLASS PERIOD: November ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][8]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [8]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline [8]. Group 3: Financial Impact - Following the announcement of the trial results, Vistagen's stock price fell from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, representing a decline of more than 80% [8].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Coupang, Inc. regarding a class action lawsuit due to allegations of misleading statements and inadequate cybersecurity protocols that led to a data breach affecting customer information [1][3]. Group 1: Allegations - The complaint alleges that during the class period from May 7, 2025, to December 16, 2025, Coupang issued materially false and misleading statements [3]. - It is claimed that Coupang had inadequate cybersecurity measures, allowing a former employee to access sensitive customer information for nearly six months without detection [3]. - The company is accused of failing to disclose the data breach in compliance with SEC reporting rules, which heightened the risk of regulatory scrutiny [3]. Group 2: Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline set for February 17, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for failing to disclose critical information regarding its business strategy and financial performance during the class period from June 4, 2024, to November 19, 2025 [2][6]. Allegation Details - The lawsuit alleges that Bath & Body Works did not disclose that its strategy of pursuing "adjacencies, collaborations and promotions" was ineffective in growing its customer base and did not deliver the expected growth in net sales [6]. - It is claimed that as the strategy faltered, the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [6]. - On November 20, 2025, the company reported disappointing third-quarter results, with a 1% year-over-year revenue decline, missing the guidance of 1-3% growth, and a 26% drop in net income to $77 million [6]. Financial Performance - Bath & Body Works reduced its full-year guidance for net sales and cut expected earnings per diluted share from $3.28 to "at least $2.83" [6]. - Following the announcement of its underperformance and new business strategy, the stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [6]. Next Steps - Investors who purchased Bath & Body Works shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4].

Core Viewpoint - The consumer center in North Rhine-Westphalia, Germany, has initiated a collective lawsuit against Amazon, demanding refunds for consumers affected by the price increase of the Prime membership, with eligible consumers potentially receiving up to €60 in compensation [1][4]. Group 1: Price Increase Details - On September 15, 2022, Amazon unilaterally raised the annual Prime membership fee from €69 to €89 and the monthly fee from €7.99 to €8.99 [1]. - The Prime Student membership also saw an increase, with the annual fee rising from €34 to €44.90 and the monthly fee from €3.99 to €4.49 [1]. Group 2: Legal Claims and Consumer Rights - Consumers argue that Amazon's price increase was conducted without explicit consent, claiming that the service terms contain unfair content and lack sufficient transparency [4]. - The consumer center asserts that Amazon's unilateral price increase is illegal and demands the difference between the original and increased prices be refunded [4]. - The amount consumers can reclaim varies based on the duration of their subscription post-price increase and their chosen payment method, with the maximum recoverable amount currently estimated at €60, which may increase as the lawsuit progresses [4].